BiologicalDrug
Simtuzumab clinical trials
Also written GS-6624 and AB0024.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How studies write it
Studies that test it under each name
Name
- SIM
- 3
Studies by the year they started
12 studies that test it; most in 2012 (4)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 4 |
| 2013 | 2 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses simtuzumab is read from its arms, and is right about nine times in ten.
Testing it · 12
- Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver FibrosisCompletedPhase 2Gilead SciencesNCT01707472Written as Simtuzumab
- Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)CompletedPhase 2Gilead SciencesNCT01672853Written as Simtuzumab
- Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3CompletedPhase 2Gilead SciencesNCT02466516Written as SIM
- Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal AdenocarcinomaTerminatedPhase 2Gilead SciencesNCT01479465Written as Simtuzumab
- Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)TerminatedPhase 2Gilead SciencesNCT01672866Written as SIM
- Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASHTerminatedPhase 2Gilead SciencesNCT01672879Written as SIM
- Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)TerminatedPhase 2Gilead SciencesNCT01769196Written as Simtuzumab
- Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)TerminatedPhase 2Gilead SciencesNCT01759511Written as Simtuzumab
- A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary FibrosisCompletedPhase 1Gilead SciencesNCT01362231Written as GS-6624
- A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic AdenocarcinomaCompletedPhase 2Gilead SciencesNCT01472198Written as Simtuzumab
- Pilot Study of Simtuzumab in the Treatment of Liver FibrosisCompletedPhase 2Gilead SciencesNCT01452308Written as Simtuzumab
- First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid TumorsCompletedPhase 1Gilead SciencesNCT01323933Written as AB0024
Given in every arm · 1 — simtuzumab is usual care beside what is tested
Codes
What other systems call simtuzumab · ClinicalTrials.gg INT000584
- MeSH (NLM) C000613471simtuzumabOne source NLM
- UNII (FDA) 11Z5AIU653SIMTUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7521275SimtuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91735SimtuzumabOne source FDA
- DrugBank DB12152One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000613471 | simtuzumab | One source NLM |
| UNII (FDA) | 11Z5AIU653 | SIMTUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7521275 | Simtuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91735 | Simtuzumab | One source FDA |
| DrugBank | DB12152 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.